What is Cellphire?
Cellphire Therapeutics operates at the intersection of biotechnology and emergency medicine, specializing in the development of innovative platelet-derived therapeutics. The company's core mission is to mitigate the risks associated with controllable hemorrhage, which remains a primary driver of preventable mortality in both military and civilian trauma scenarios. Their flagship product portfolio, featuring freeze-dried platelet-derived hemostats and cryopreserved platelets, is currently undergoing Phase 2 clinical evaluation. By focusing on the stabilization and delivery of advanced cellular therapies, Cellphire is effectively redefining the standard of care for patients suffering from acute bleeding disorders during surgery or traumatic injury.
How much funding has Cellphire raised?
Cellphire has raised a total of $20.6M across 5 funding rounds:
Debt
$1M
Other Financing Round
$1.3M
Other Financing Round
$3M
Debt
$350K
Series A
$15M
Debt (2014): $1M, investors not publicly disclosed
Other Financing Round (2016): $1.3M led by Maryland Department of Commerce
Other Financing Round (2017): $3M supported by Maryland Department of Commerce
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Simcah Management
Key Investors in Cellphire
Simcah Management
A private investment firm focused on identifying high-growth opportunities within the healthcare and biotechnology sectors.
Maryland Department of Commerce
A state-level agency dedicated to fostering economic growth and supporting innovation-driven enterprises within the Maryland biotechnology corridor.
PPP
Public-Private Partnership
What's next for Cellphire?
With the recent infusion of capital, Cellphire is poised to prioritize the advancement of its clinical trials, specifically targeting the completion of Phase 2 studies for its hemostatic agents. The strategic roadmap involves scaling manufacturing capabilities to meet potential demand for military and civilian medical applications. Furthermore, the company is expected to focus on regulatory engagement to streamline the path toward commercialization. As the firm matures, investors will likely monitor the efficacy data emerging from ongoing trials, which will serve as the primary indicator for future valuation growth and potential market entry strategies in the global trauma care sector.
See full Cellphire company page
